Stillwater Investment Management has a 13F portfolio value of $141.99 million, as per its recent SEC 13F filing on October 6, 2014. Its top 10 holdings amount for 47.91% of its overall portfolio. Apple Inc. (NASDAQ:AAPL), Gilead Sciences, Inc. (NASDAQ:GILD), Johnson & Johnson (NYSE:JNJ) are among the top stock holdings of Stillwater Investment Management.

With a proven performance of several years and the iconic iPhone in its portfolio, Apple Inc. (NASDAQ:AAPL) makes it to the portfolio of several hedge funds including Stillwater Investment Management, which owns 47,821 shares of the company with market value of $4.81 million. The iPhone maker generated net revenue of $37.4 billion in its third quarter 2014 while generating net profits of $7.7 billion. Some of the primary investors of Apple Inc (NASDAQ:AAPL) include Icahn Capital investing $4.9 billion in the company. Soroban Capital Partners is the second largest investor at $2.46 billion followed by Citadel Investment Group ($1.61 billion).

Gilead Sciences, Inc. (NASDAQ:GILD) comes at number two in Stillwater Investment Management’s portfolio with 33,403 shares and investments exceeding $3.55 million. Gilead Sciences, Inc. (NASDAQ:GILD) managed to generate net revenues of $6.53 billion during the second quarter 2014 with its net income standing at $3.66 billion. When it comes to the investors of Gilead Sciences, Inc. (NASDAQ:GILD), Egerton Capital Limited is comes first at $509 million with Orbis Investment Management standing at number two ($509 million) and Columbus Circle Investors ($398 million) comes at number three.

Stillwater Investment Management has Johnson & Johnson (NYSE:JNJ) as its third largest investment with investments standing at $3.22 million and 30,228 shares. Johnson & Johnson (NYSE:JNJ) raised net sales of $19.5 billion in the second quarter 2014 and registered net earnings of $4.3 billion. Some of its primary investors include Fisher Asset Management ($1.09 billion), Yacktman Asset Management ($946 million), and Aqr Capital Management ($381 million).

This article has been written by Prakash Pandey and edited by Serkan Unal.

Related News: “Gilead Sciences, Inc. (GILD) Says Pancreatic Cancer Treatment, Simtuzumab, Failed to Meet Trial Goals in Phase II”

“Gilead Sciences, Inc. (GILD) Strikes Deal for Cheaper Hepatitis C Drugs for Developing Countries”

Read: Warren Buffett and Billionaires Are Crazy About These 7 Stocks

Read: The 10 Most Used Social Media Websites Today